Roche Accu-Chek Aviva Plus
The technology used in the Roche Accu-Chek Aviva Plus, to measure blood glucose, is among the best rated for accuracy by Medaval Ltd. It has passed in clinical validation studies, between general and specific populations, according to recognised standard protocols, as published in peer-reviewed publications.
|Medaval||★★★ Recommendation||Recent clinical validation; recent protocol; multiple clinical validations|
|Consumer Reports (US)||2019-2021||Excellent|
|Amazon Best Sellers (US)||2019||A (4.3 / 5)|
Brazg RL, Klaff LJ, Parkin CG. Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. J Diabetes Sci Technol. 2013 Jan 1;7(1):144-52. doi: 10.1177/193229681300700117. PMID: 23439170. Available from: PMC3692226.
15197:2003 - Pass General population (Note: Validation against HK control)
15197:2003 - Pass General population (Note: YSI control)
Klonoff DC, Parkes JL, Kovatchev BP, Kerr D, Bevier WC, Brazg RL, Christiansen M, Bailey TS, Nichols JH, Kohn MA. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care. 2018 Aug;41(8):1681-8. Epub: 2018 Jun 13. doi: 10.2337/dc17-1960. PMID: 29898901. Available from: www.diabetestechnology.org.
DTS:2016 - Pass General population
Tentolouris A, Eleftheriadou I, Grigoropoulou P, Nikoloudi M, Siami E, Tsilimigras DI, Tentolouris N. Accuracy and Usability Evaluation of Six Commercially Available Blood Glucose Monitoring Systems Journal of Clinical and Diagnostic Research. 2018 Jun;12(6):OC10-OC14. doi: 10.7860/JCDR/2018/34055.11671. Available from: www.jcdr.net.
Ad Hoc protocol General population (Note: Tested in criteria resembling ISO 15197:2013.)